Ligand Pharmaceuticals Inc. (LGND)
NASDAQ · Healthcare
Ligand Pharmaceuticals Inc. Shareholder Equity 2009–2025
Ligand Pharmaceuticals Inc. annual shareholder equity history from 2010 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Ligand Pharmaceuticals Inc. shareholder equity as of December 31, 2025: 1.02B, a 22.49% increase year-over-year.
- Ligand Pharmaceuticals Inc. shareholder equity for 2025 were 1.02B, a 22.49% increase from 2024.
- Ligand Pharmaceuticals Inc. shareholder equity for 2024 were 830.4M, a 18.48% increase from 2023.
- Ligand Pharmaceuticals Inc. shareholder equity for 2023 were 700.9M, a 17.31% increase from 2022.
- Ligand Pharmaceuticals Inc. shareholder equity for 2022 were 597.5M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Ligand Pharmaceuticals Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $1,017 |
| 2024 | $830 |
| 2023 | $701 |
| 2022 | $597 |
| 2021 | $821 |
| 2020 | $710 |
| 2019 | $767 |
| 2018 | $561 |
| 2017 | $400 |
| 2016 | $341 |
| 2015 | $237 |
| 2014 | $26 |
| 2013 | $50 |
| 2012 | $26 |
| 2011 | $8 |
Ligand Pharmaceuticals Inc. Shareholder Equity — FAQ
Ligand Pharmaceuticals Inc. (LGND) shareholder equity over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LGND's shareholder equity history?
The chart and table above show Ligand Pharmaceuticals Inc.'s shareholder equity by year and by quarter, including the growth rate.